Madam is an acronym for Molecular Anti-infective Drugs from Amsterdam. We are an innovative biotech start-up developing a novel technology platform of anti-infectives. The technology platform is based on a family of antimicrobial peptides, which are derived from naturally occurring proteins/peptides that combat bacterial infections. They have a distinct mechanism of action from conventional antibiotics.
The key advantage is that the development of resistance against these peptides is highly unlikely, due to their multiple modes of action. Our unique family of ‘2nd generation’ peptides which we develop jointly with the University of Leiden has an improved antibacterial activity against antibiotic resistant bacteria, including methicillin-resistant
Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa.
MRSA is the most important cause of diseases and problems related to antibiotic-resistant infections worldwide, including in the pathogenesis of atopic eczema, a very common skin disorder.
Lack of success in the treatment of burn wounds is another common problem due to infection of the wound with antibiotic-resistant bacterial strains, often Pseudomonas aeruginosa and MRSA. Our peptides address the fast growing and unmet medical need for new treatment options for patients suffering from difficult to treat infections due to antimicrobial resistance, which is estimated to cost the global health care system over 10 billion Euro per year.